Wolfe Research analyst Kalpit Patel initiated coverage of Oric Pharmaceuticals (ORIC) with a Peer Perform rating and no price target The firm highlights the baseline imbalance in Pfizer’s (PFE) mevro study and thinks that the magnitude of benefit may be overstated with the PRC2 inhibitor drug class.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ORIC:
- Oric Pharmaceuticals price target raised to $16 from $12 at Citi
- Oric Pharmaceuticals’ 2025 Restructuring: Potential Risks and Financial Implications
- Promising Potential of ORIC-944 in mCRPC Treatment Boosts Buy Rating and Price Target
- Oric Pharmaceuticals price target raised to $23 from $19 at H.C. Wainwright
- Promising Developments and Strong Cash Position Justify Buy Rating for ORIC Pharmaceuticals